Catalyst Pharmaceuticals Stock Investor Sentiment
| CPRX Stock | USD 22.07 0.27 1.21% |
Slightly above 56% of Catalyst Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Catalyst Pharmaceuticals suggests that many traders are alarmed. Catalyst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Catalyst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
44
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Catalyst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Catalyst Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Catalyst Historical Sentiment
Although Catalyst Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Catalyst, such as negative comments on social media and news outlets, may cause fear in the market and push Catalyst Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Catalyst.
Catalyst |
Catalyst Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 60000 shares by Okeeffe Charles B of Catalyst Pharmaceuticals at 1.13 subject to Rule 16b-3 | 09/27/2024 |
2 | Should You Invest in the First Trust NYSE Arca Biotechnology ETF | 10/07/2024 |
3 | Disposition of 3410 shares by Grande Alicia of Catalyst Pharmaceuticals subject to Rule 16b-3 | 10/25/2024 |
4 | Are Medical Stocks Lagging Bioventus This Year | 11/04/2024 |
5 | Earnings call Catalyst Pharma reports robust Q3 results, raises guidance | 11/07/2024 |
6 | With EPS Growth And More, Catalyst Pharmaceuticals Makes An Interesting Case | 11/08/2024 |
7 | Disposition of 230000 shares by Patrick McEnany of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3 | 11/11/2024 |
8 | Disposition of 192000 shares by Patrick McEnany of Catalyst Pharmaceuticals at 3.54 subject to Rule 16b-3 | 11/12/2024 |
9 | We Think Catalyst Pharmaceuticals Profit Is Only A Baseline For What They Can Achieve | 11/13/2024 |
10 | Are You a Value Investor This 1 Stock Could Be the Perfect Pick | 11/14/2024 |
11 | Disposition of 98345 shares by Patrick McEnany of Catalyst Pharmaceuticals at 3.54 subject to Rule 16b-3 | 11/19/2024 |
12 | Disposition of 72500 shares by Patrick McEnany of Catalyst Pharmaceuticals at 3.54 subject to Rule 16b-3 | 11/20/2024 |
13 | Acquisition by Thompson Tamar of 23248 shares of Catalyst Pharmaceuticals at 21.12 subject to Rule 16b-3 | 11/21/2024 |
14 | Catalyst Pharmaceuticals chief medical officer sells 805,562 in stock | 11/22/2024 |
15 | Catalyst Pharmaceuticals Recognized as One of North Americas Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List | 11/25/2024 |
16 | Disposition of 9300 shares by Elsbernd Brian of Catalyst Pharmaceuticals at 21.65 subject to Rule 16b-3 | 11/26/2024 |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.